Business
OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies
OSR Holdings, Inc. ("OSR") (NASDAQ: OSRH), a global healthcare company focused on advancing innovative therapies, today announced that it has entered into a Common Stock Purchase Agreement with White Lion GBM Innovation Fund ("Innovation Fund"). Under this agreement, OSR has the right, but not the obligation, to sell up to $80 million in common stock to Innovation Fund over time, which will prospectively provide OSR with critical funding to accelerate its mission of improving patient outcomes wo
About this update from Osr Holdings, Inc.
[{"type":"text","content":"SEOUL, South Korea, April 3, 2025 /PRNewswire/ -- OSR Holdings, Inc. ("OSR") (NASDAQ: OSRH), a global healthcare company focused on advancing innovative therapies, today announced that it has entered into a Common Stock Purchase Agreement with White Lion GBM Innovation Fund ("Innovation Fund"). Under this agreement, OSR has the right, but not the obligation, to sell up to $80 million in common stock to Innovation Fund over time, which will prospectively provide OSR with critical funding to accelerate its mission of improving patient outcomes worldwide.","length":583,"tagName":"p"},{"type":"image","alt":"OSR Holdings logo (PRNewsfoto/OSR Holdings)","displaySize":"","headline":null,"caption":"OSR Holdings logo (PRNewsfoto/OSR Holdings)","className":"","disableSlideshowImg":false,"size":{"original":{"width":334,"height":277,"url":"https://media.zenfs.com/en/prnewswire.com/d1cf26310f8a0d3a1f4f003318d5e702"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cTh6l6BCVhUkYFTe3KonaA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTUzMTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/d1cf26310f8a0d3a1f4f003318d5e702","width":334,"height":277}},"href":"https://mma.prnewswire.com/media/2393302/OSR_Holdings_logo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Transforming Global Healthcare Through Innovation","length":49,"tagName":"p","attribs":{}},{"type":"text","content":"OSR Holdings is committed to transforming the healthcare landscape through a diverse portfolio of cutting-edge biomedical initiatives. The company's global network spans the United States, Europe, and Asia, focusing on oncology, immunotherapy, and medical devices. Among its key subsidiaries, OSR is advancing Vaximm, a Swiss-based biotech developing a novel GBM vaccine (VXM01) aimed at enhancing immune response against glioblastoma."This transaction is a major cornerstone in our plans to bring transformative therapies to market," said Peter Hwang, CEO, OSR Holdings. "Glioblastoma remains one of the most challenging cancers, and we anticipate that establishing this financing facility will enable us to advance our Vaximm immunotherapy platform and other innovative healthcare solutions.","length":814,"tagName":"p"},{"type":"text","content":""We anticipate that this collaboration with Innovation Fund will al...